Cefditoren dosage and administration: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 8: | Line 8: | ||
| [[File:SPECTRACEF05.jpg|800px|thumb]] | | [[File:SPECTRACEF05.jpg|800px|thumb]] | ||
|} | |} | ||
====Patients with Renal Insufficiency==== | ====Patients with Renal Insufficiency==== | ||
No dose adjustment is necessary for patients with mild renal impairment (CLcr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (CLcr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (CLcr: <30 mL/min/1.73 m2). The appropriate dose in patients with end-stage renal disease has not been determined. | No dose adjustment is necessary for patients with mild renal impairment (CLcr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (CLcr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (CLcr: <30 mL/min/1.73 m2). The appropriate dose in patients with [[end-stage renal disease]] has not been determined. | ||
====Patients with Hepatic Disease==== | ====Patients with Hepatic Disease==== | ||
Latest revision as of 01:41, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Dosage and Administration
 |
Patients with Renal Insufficiency
No dose adjustment is necessary for patients with mild renal impairment (CLcr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (CLcr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (CLcr: <30 mL/min/1.73 m2). The appropriate dose in patients with end-stage renal disease has not been determined.
Patients with Hepatic Disease
No dose adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). The pharmacokinetics of cefditoren have not been studied in patients with severe hepatic impairment (Child-Pugh Class C).[1]
References
Adapted from the FDA Package Insert.